Table 2 Patient information for predominant histological subtypes in all cases

n

2863

304

526

1745

287

Sex (male/Female), n (%)

1478/1385 (51.6%)

119/185 (39.1%)

233/293 (44.3%)

940/805

(53.8%)

185/102

(64.4%)

 < 0.001

Age, mean ± SD

66.71 ± 9.15

66.49 ± 9.67

67.72 ± 8.20

66.46 ± 9.23

65.88 ± 9.38

0.025

Smoking history ( ±), n (%)

1471 / 1308 (52.9%)

110/187

(37.0%)

222 / 292 (43.2%)

741 / 594 (55.5%)

205 / 72

(74.0%)

 < 0.001

Operation time (min.), mean ± SD

205.25 ± 66.89

203.47 ± 62.70

198.60 ± 66.50

207.41 ± 67.76

204.13 ± 66.12

0.017

Invasion, n (%)

 Lymph vessel invasion ( ±), n (%)

777 / 1785 (30.3%)

0 / 273

(0%)

76 / 412 (15.6%)

565 / 978 (36.6%)

131 / 130 (50.2%)

 < 0.001

 Vascular invasion ( ±), n (%)

695 / 1875 (27.3%)

0 / 278

(0%)

49 / 440

(10.0%)

494 / 1059

(31.8%)

152 / 111

(57.8%)

 < 0.001

Pleural invasion ( ±), n (%)

691 / 2156 (24.3%)

0 / 316 (0%)

63/ 461 (12.1%)

517 / 1224

(29.7%)

111 / 174

(38.9%)

 < 0.001

 EGFR mutation ( ±)

641 / 783 (45.0%)

72 / 54 (57.1%)

118 / 96 (55.1%)

426 / 522

(44.9%)

33 / 122　(21.3%)

 < 0.001

 Adjuvant therapy ( ±)

1017 / 1820 (35.8%)

17 / 287 (5.9%)

152 / 368 (29.2%)

697 / 1034

(40.3%)

143 / 140 (50.5%)

 < 0.001

 Clinical stage

IA / IB / IIA / IIB / IIIA

1732 / 749 / 190 / 83 / 98

272 / 31 / 1 / 0 / 0

316 / 171 / 22 / 9 / 8

1015 / 462 / 132 / 59 / 77

143 / 82 / 32 / 11 / 19

 < 0.001

 Pathological stage

IA / IB / IIA / IIB / IIIA

1426 / 732 / 260 / 110 / 314

298 / 6 / 0 / 0 / 0

319 / 150 / 18 / 7 / 32

749 / 493 / 195 / 75 / 233

82 / 68 / 50 / 23 / 64

 < 0.001